Maxim Group lowered shares of Citius Oncology (NASDAQ:CTOR - Free Report) from a strong-buy rating to a hold rating in a report issued on Friday morning, Marketbeat.com reports.
Citius Oncology Stock Performance
NASDAQ:CTOR traded up $0.01 on Friday, reaching $0.90. 13,824 shares of the company's stock were exchanged, compared to its average volume of 1,077,956. Citius Oncology has a 52-week low of $0.55 and a 52-week high of $4.42. The company has a quick ratio of 0.08, a current ratio of 0.34 and a debt-to-equity ratio of 0.08. The business has a fifty day moving average of $0.78 and a 200-day moving average of $0.99.
Citius Oncology (NASDAQ:CTOR - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.02).
Institutional Investors Weigh In On Citius Oncology
An institutional investor recently bought a new position in Citius Oncology stock. Citadel Advisors LLC purchased a new stake in shares of Citius Oncology, Inc. (NASDAQ:CTOR - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 22,699 shares of the company's stock, valued at approximately $26,000. Hedge funds and other institutional investors own 70.52% of the company's stock.
Citius Oncology Company Profile
(
Get Free Report)
Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma.
Recommended Stories
Before you consider Citius Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Citius Oncology wasn't on the list.
While Citius Oncology currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
